Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Completed · Phase 1

Conditions studied: Bacterial Infections

In brief

Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.

Key facts

Study ID

NCT00678106

Run by

Pfizer

People needed

10

Starts

2008-09-01

Expected to finish

2009-07-01

Last updated by the study team

2009-10-12

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 12 to 17 year old adolescents hospitalized for the treatment of bacterial infections.

You may not qualify if…

• Patients being treated with vancomycin.
• Patients with liver and kidney failure.
• Pregnant female subjects.

Where it is running

• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.